Velcade Related Published Studies
Well-designed clinical trials related to Velcade (Bortezomib)
Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression. [2011.08.15]
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. [2011.08]
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. [2011.05]
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. [2011.05]
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. [2011.03.01]
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. [2011.01]
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. [2011.01]
Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. [2011.01]
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. [2010.12.18]
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. [2010.12.02]
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. [2010.12.01]
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. [2010.11.11]
Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinaemia. [2010.11]
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. [2010.11]
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. [2010.10.20]
A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. [2010.10.15]
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. [2010.10]
Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. [2010.08]
A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. [2010.06]
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. [2010.05.01]
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. [2009.12.20]
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma. [2009.11]
A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. [2009.08]
Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. [2009]
Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study. [2009]
Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. [2008.12]
Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. [2008.11]
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. [2008.11]
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. [2008.10.10]
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. [2008.08.28]
Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study. [2008.05.10]
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. [2008.04]
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. [2007.09.01]
A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. [2007.03.15]
Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. [2006.09.01]
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. [2006.07]
Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. [2006.02]
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. [2005.06.16]
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. [2004.10]
Well-designed clinical trials possibly related to Velcade (Bortezomib)
Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma. [2011.10]
Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. [2011.03.17]
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. [2011.03.10]
Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. [2011.01]
Management options for cast nephropathy in multiple myeloma. [2010.11]
Management options for cast nephropathy in multiple myeloma. [2010.09.08]
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. [2010.05.27]
The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review. [2009.08]
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. [2008.10.15]
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. [2008.10]
Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. [2008.09]
Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. [2008.07]
Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. [2008.06.20]
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized, controlled trial. [2008.05.27]
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. [2007.11.15]
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. [2007.04.01]
PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study. [2005.10]
Other research related to Velcade (Bortezomib)
Cytogenetic and clinical marks for defining high-risk myeloma in the context of
bortezomib treatment. [2015]
Bortezomib-thalidomide-based regimens improved clinical outcomes without
increasing toxicity as induction treatment for untreated multiple myeloma: a
meta-analysis of phase III randomized controlled trials. [2014]
Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with
bortezomib but copy number variation and percentage of plasma cells involved have
no additional prognostic value. [2014]
Bortezomib-cyclophosphamide-dexamethasone (VCD) versus
bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies
in newly diagnosed transplant eligible patients with multiple myeloma: a
meta-analysis. [2014]
Bortezomib and lenalidomide as front-line therapy for multiple myeloma. [2014]
Zonisamide: a review of its use in the management of adults with partial
seizures. [2013]
Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib
versus bortezomib in relapsed or refractory multiple myeloma. [2013]
Bortezomib induction and maintenance treatment in patients with newly diagnosed
multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. [2012]
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone
over the dual combination of thalidomide-dexamethasone in patients with multiple
myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM
2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the
European Group for Blood and Marrow Transplantation. [2012]
Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as
first-line therapy in patients with advanced non-small-cell lung cancer. [2012]
Impact of bortezomib on bone health in myeloma: a review of current evidence. [2012]
Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-Hodgkin's Lymphoma. [2011.12.01]
The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation. [2011.12]
Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial. [2011.11.10]
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. [2011.10.27]
Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo. [2011.10.12]
Response of myeloma to proteasome inhibitor bortezomib is correlated with unfolded protein response regulator XBP-1. [2011.10.11]
Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China. [2011.10]
Successful treatment with bortezomib and thalidomide for POEMS syndrome associated with multicentric mixed-type Castleman's disease. [2011.10]
Bortezomib-dexamethasone or vincristine-Doxorubicin-dexamethasone as induction therapy followed by thalidomide as maintenance therapy in untreated multiple myeloma patients. [2011]
Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib. [2011]
The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide
in combination regimens with an alkylating agent and a corticosteroid for the
first-line treatment of multiple myeloma: a systematic review and economic
evaluation. [2011]
Bortezomib for previously untreated multiple myeloma. [2011]
A steroid-independent regimen of bortezomib, liposomal doxorubicin and
thalidomide demonstrate high response rates in newly diagnosed multiple myeloma
patients. [2011]
Subcutaneous versus intravenous administration of bortezomib in patients with
relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. [2011]
Randomized phase II trial of concurrent versus sequential bortezomib plus
docetaxel in advanced non-small-cell lung cancer: a California cancer consortium
trial. [2011]
Genetic variation associated with bortezomib-induced peripheral neuropathy. [2011]
Bortezomib and dexamethasone for Japanese patients with relapsed and refractory multiple myeloma: a single center experience. [2010.10.02]
Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinaemia. [2010.09.29]
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. [2010.09.21]
Multigene Expression-Based Predictors for Sensitivity to Vorinostat and Velcade in Non-Small Cell Lung Cancer. [2010.09.21]
The Cost-Effectiveness of Bortezomib in Relapsed/Refractory Multiple Myeloma: Swedish Perspective. [2010.09.16]
An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. [2010.09.14]
Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial. [2010.09.07]
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom Macroglobulinemia. [2010.09]
Efficacy and safety of once weekly bortezomib in multiple myeloma patients. [2010.08.31]
A Phase I/II Trial Combining High Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study. [2010.08.25]
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. [2010.08.23]
Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. [2010.07.27]
Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma. [2010.07.20]
Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia. [2010.06]
A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. [2009.11]
Multicenter Randomized Phase II Study of Weekly or Twice-Weekly Bortezomib Plus Rituximab in Patients With Relapsed or Refractory Follicular or Marginal-Zone B-Cell Lymphoma. [2009.10.20]
Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). [2009.10.01]
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. [2009.10]
|